After today's changes (ASMi out, UCB in), we maintain a balanced approach in our Dynamic Top Pick List, with a particular emphasis on value stocks that have been overlooked. Our defensive holdings are overweight, including real estate, which stands to benefit from lower interest rates. We remove ASMi from our Dynamic Top Pick List as the recent share price performance has driven the valuation meaningfully ahead of fundamentals. Since early December, FY27 diluted EPS expectations have risen by a...
After a string of multi-GW contracts and capex announcements, the attractiveness of cloud AI returns remains a hot question amongst investors. In this report, we build a simple framework to answer that question. We estimate Cloud AI returns from CSP disclosures and what we know about large real-world contracts, and benchmark them against what we know about the economics of traditional cloud.
We refresh our ING Benelux Favourites list. We apply a fundamental bottom up approach in which we select stocks which provide the best upside within our Benelux coverage universe and these stocks need clear catalysts. Additions/deletions: We add the following names to the ING Benelux Favourites list: Ageas: Ageas has done multiple deals; its most recent purchase of the 25% stake BNP Paribas had in its Belgian ops, is an accretive deal and we believe makes the Belgian operations ready for a pot...
ASM's 4Q25 order intake beat has transformed the 3Q25 disappointment into just a one-off timing hiccup within a very strong long-term growth path. TSMC's FY26 capex beat underlines that AI strength and ongoing technology transitions are key tailwinds for ASM. We expect the company to significantly outgrow its peers. We meaningfully increase our estimates, up our DCF-based target price to €900 per share (from €700) and reiterate our BUY. ASM remains on the ING Benelux Favourites list.
ASM pre-announces Q4 bookings and revenue ahead of expectations Almere, The NetherlandsJanuary 19, 2026, 8:00 a.m. CET ASM International N.V. (Euronext Amsterdam: ASM) today announces, based on preliminary figures, Q4 bookings of approximately €800 million, well above the prior indication, and Q4 revenue of €698 million, which also exceeded the previously guided range of €630-660 million. Order intake in Q4 2025 rose to approximately €800 million, well above the indication provided with the Q3 2025 results that bookings would be at a level slightly above the €637 million recorded in Q3...
A director at Argen X SE sold after exercising options/sold 3,625 shares at 695.710EUR and the significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over t...
argenx announced that the FDA has accepted for priority review a sBLA for Vyvgart IV for the treatment of adults with acetylcholine receptor antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG), with a PDUFA target action date of 10 May 2026. The sBLA acceptance and priority review for Vyvgart in seronegative gMG brings argenx a step closer to its aim of having the broadest possible label in this setting. argenx estimates the commercial opportunity for seronegative gMG could add 1...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.